Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$0.50 USD
+0.02 (4.20%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.48 -0.02 (-3.23%) 5:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ADTX 0.50 +0.02(4.20%)
Will ADTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADTX
Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
ADTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Other News for ADTX
Aditxt and Evofem amend merger agreement
Aditxt files to sell $150M of common stock for holders
Aditxt files to sell $150M of common stock
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic? Prostate Test, Targeting Early Detection in High-Risk Patients
Aditxt?s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic? Endometriosis Test (MET?) and Mitomic? Prostate Test (MPT?)